Subcortical structures in amyotrophic lateral sclerosis

Westeneng, Henk Jan; Verstraete, Esther; Walhout, Renée; Schmidt, Ruben; Hendrikse, Jeroen; Veldink, Jan H.; Heuvel, Martijn P. van den; Berg, Leonard H. van den

doi:10.1016/j.neurobiolaging.2014.09.002

Cited by 82 publications

(78 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, TA may precede true volumetric changes, as we only found differences between groups in the FreeSurfer analysis at the right thalamus, and there was no correlation between TA parameters and volumes. This result is in line with a recently published longitudinal study that failed to identify progressive atrophy of DGN over time in the disease.…”

Section: Discussionsupporting

confidence: 92%

MRI Texture Analysis Reveals Deep Gray Nuclei Damage in Amyotrophic Lateral Sclerosis

Albuquerque

Anjos

Andrade

et al. 2015

Journal of Neuroimaging

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

MRI Texture Analysis Reveals Deep Gray Nuclei Damage in Amyotrophic Lateral Sclerosis

Albuquerque

Anjos

Andrade

et al. 2015

Journal of Neuroimaging

View full text Add to dashboard Cite

show abstract

“…The finding of memory changes in our meta-analysis ,therefore, could reflect changes in the MTL, which have been described as TDP-43 positive neuronal inclusions in the dentate gyrus, hippocampus and transentorhinal cortex, found in postmortem studies of patients with ALS, in particular when concomitant dementia was present 34. Recent MRI studies underlined the involvement of the MTL in non-demented patients with ALS by correlating hippocampal volume with impairment of verbal memory 35 36…”

Section: Discussionmentioning

confidence: 71%

The cognitive profile of ALS: a systematic review and meta-analysis update

Beeldman

Raaphorst

Twennaar

et al. 2015

J Neurol Neurosurg Psychiatry

262

206

View full text Add to dashboard Cite

Cognitive impairment is present in approximately 30% of patients with amyotrophic lateral sclerosis (ALS) and, especially when severe, has a negative impact on survival and caregiver burden. Our 2010 meta-analysis of the cognitive profile of ALS showed impairment of fluency, executive function, language and memory. However, the limited number of studies resulted in large confidence intervals. To obtain a more valid assessment, we updated the meta-analysis and included methodological improvements (controlled data extraction, risk of bias analysis and effect size calculation of individual neuropsychological tests). Embase, Medline and PsycInfo were searched for neuropsychological studies of non-demented patients with ALS and age-matched and education-matched healthy controls. Neuropsychological tests were categorised in 13 cognitive domains and effect sizes (Hedges' g) were calculated for each domain and for individual tests administered in ≥5 studies. Subgroup analyses were performed to assess the influence of clinical and demographic variables. Forty-four studies were included comprising 1287 patients and 1130 healthy controls. All cognitive domains, except visuoperceptive functions, showed significant effect sizes compared to controls. Cognitive domains without bias due to motor impairment showed medium effect sizes (95% CI): fluency (0.56 (0.43 to 0.70)), language (0.56 (0.40 to 0.72)), social cognition (0.55 (0.34 to 0.76)), or small effect sizes: delayed verbal memory 0.47 (0.27 to 0.68)) and executive functions (0.41 (0.27 to 0.55)). Individual neuropsychological tests showed diverging effect sizes, which could be explained by bias due to motor impairment. Subgroup analyses showed no influence of bulbar disease onset and depression and anxiety on the cognitive outcomes. The cognitive profile of ALS consists of deficits in fluency, language, social cognition, executive functions and verbal memory. Social cognition is a new cognitive domain with a relatively large effect size, highlighting the overlap between ALS and frontotemporal dementia. The diverging effect sizes for individual neuropsychological tests show the importance of correction for motor impairment in patients with ALS. These findings have implications for bedside testing, the design of cognitive screening measures and full neuropsychological examinations.

show abstract

“…The change in the volume of subcortical gray matter structures and ventricles in 39 patients with ALS was assessed over an interval of on average 5.5 months [115], and significant shrinkage of the right cornu ammonis 2/3 and cornu ammonis 4/dentate gyrus was observed, as well as enlargement of both lateral, the right inferior lateral, and third and fourth ventricles.…”

Section: Emerging Imaging Biomarkers In Alsmentioning

confidence: 99%

Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis

et al. 2017

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative, clinically heterogeneous syndrome pathologically overlapping with frontotemporal dementia. To date, therapeutic trials in animal models have not been able to predict treatment response in humans, and the revised ALS Functional Rating Scale, which is based on coarse disability measures, remains the gold-standard measure of disease progression. Advances in neuroimaging have enabled mapping of functional, structural, and molecular aspects of ALS pathology, and these objective measures may be uniquely sensitive to the detection of propagation of pathology in vivo. Abnormalities are detectable before clinical symptoms develop, offering the potential for neuroprotective intervention in familial cases. Although promising neuroimaging biomarker candidates for diagnosis, prognosis, and disease progression have emerged, these have been from the study of necessarily select patient cohorts identified in specialized referral centers. Further multicenter research is now needed to establish their validity as therapeutic outcome measures.Electronic supplementary materialThe online version of this article (doi:10.1007/s13311-016-0484-9) contains supplementary material, which is available to authorized users.

show abstract

Subcortical structures in amyotrophic lateral sclerosis

Cited by 82 publications

References 37 publications

MRI Texture Analysis Reveals Deep Gray Nuclei Damage in Amyotrophic Lateral Sclerosis

MRI Texture Analysis Reveals Deep Gray Nuclei Damage in Amyotrophic Lateral Sclerosis

The cognitive profile of ALS: a systematic review and meta-analysis update

Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About